AbbVie Inc. closed 15.68% short of its 52-week high of $207.32, which the company achieved on October 31st.

AbbVie Inc. closed 14.67% below its 52-week high of $207.32, which the company achieved on October 31st.

That makes AbbVie a solid buy today. Justin Pope has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie and Abbott Laboratories. The Motley Fool has ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target of $224.00. The company’s shares closed yesterday ...

Piper Sandler analyst Christopher Raymond raised the firm’s price target on AbbVie (ABBV) to $227 from $220 and keeps an Overweight rating on the shares ahead of earnings. With biotech having ...

AbbVie (NYSE:ABBV) will report Q4 2024 results ... I think there is room for outperformance in 2025, but I see no need for the company to start the year with aggressive guidance.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie and Goldman Sachs Group. The Motley Fool has a disclosure policy. Got $1,500?

NORTH CHICAGO, Ill. and SAN DIEGO, Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Neomorph, Inc. today announced a collaboration and option-to-license agreement to develop novel molecular glue ...

Pharmaceutical powerhouse AbbVie (NYSE: ABBV) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while ...

AbbVie. "We are pleased to welcome the talented team at Nimble who share our commitment to elevating the standard of care for people living with autoimmune diseases." For additional background on ...

Gifting allows recipients to access the article for free. Pharmaceutical giant AbbVie has inked another collaboration deal with an emerging biotech company as it seeks ways to bulk up its drug ...

AbbVie Inc (Symbol: ABBV) has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a whopping $47.94B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including ...